公开(公告)号：WO1997033563A2

公开(公告)日：1997-09-18

申请号：PCT/US1997003951

申请日：1997-03-14

Applicant: ALLIANCE PHARMACEUTICAL CORP.

Inventor： ALLIANCE PHARMACEUTICAL CORP. ,  WALTERS, Mark, A. ,  HOPKINS, Ronald, M. ,  KLEIN, David, H.

IPC: A61K09/107

CPC classification number: A61K9/0026 ,  Y10S514/825 ,  Y10S514/829 ,  Y10S977/929

Abstract: Use of fluorocarbons for the diagnosis and treatment of articular disorders is disclosed. The invention provides for the introduction of a fluorocarbon into an articular region to replace or augment natural synovial fluid. The introduced fluorocarbons, which may be in various forms including liquids, gels or emulsions, provide articular lubrification and cushioning which is effective for the treatment of disorders such as osteoarthritis and rheumatoid arthritis. Additionally, the present invention may be used to provide high resolution articular images, reduce articular inflammation and introduce bioactive agents to the articular region.

Abstract translation: 公开了氟碳化合物用于诊断和治疗关节疾病的用途。 本发明提供了将碳氟化合物引入关节区域以替代或增加天然滑液。 引入的碳氟化合物，其可以是各种形式，包括液体，凝胶或乳液，提供关节润滑和缓冲，其对于治疗诸如骨关节炎和类风湿性关节炎的病症是有效的。 此外，本发明可用于提供高分辨率关节图像，减少关节炎症并将生物活性剂引入关节区域。

公开(公告)号：WO1996040053A1

公开(公告)日：1996-12-19

申请号：PCT/US1996009081

申请日：1996-06-05

Applicant: ALLIANCE PHARMACEUTICAL CORP. ,  TREVINO, Leo, A. ,  DELLAMARY, Luis, A. ,  TARARA, Thomas, E. ,  WEERS, Jeffry, G. ,  RANNEY, Helen, M.

Inventor： ALLIANCE PHARMACEUTICAL CORP.

IPC: A61K09/00

CPC classification number: A61K9/0026 ,  Y10S514/937

Abstract: A method for preparing a pharmaceutical microdispersion exhibiting enhanced bioavailability, including the steps of providing a thermodynamically stable pharmaceutical composition comprising at least one pharmaceutical agent incorporated in a physiologically acceptable liquid carrier, the liquid carrier comprising one or more lipophilic solvents such as fluorochemicals and preferably at least one nonfluorinated co-solvent, and combining the stable pharmaceutical composition with an amount of at least one miscible diluent sufficient to initiate phase separation of the pharmaceutical agent from the pharmaceutical composition wherein a microdispersion of the pharmaceutical composition is formed. Also disclosed are microdisperse pharmaceutical compositions and kits for forming such compositions.

Abstract translation: 一种制备显示增强的生物利用度的药物微分散体的方法，包括提供包含至少一种掺入生理上可接受的液体载体中的药剂的热力学稳定的药物组合物的步骤，所述液体载体包含一种或多种亲脂性溶剂，例如含氟化合物， 至少一种非氟化共溶剂，并将稳定的药物组合物与一定量的至少一种可混溶的稀释剂组合，该稀释剂足以引发药物与药物组合物的相分离，其中形成药物组合物的微分散体。 还公开了用于形成这种组合物的微分散药物组合物和试剂盒。

公开(公告)号：WO1996040052A1

公开(公告)日：1996-12-19

申请号：PCT/US1996009067

申请日：1996-06-05

Applicant: ALLIANCE PHARMACEUTICAL CORP. ,  WEERS, Jeffry, G. ,  DELLAMARY, Luis, A. ,  TARARA, Thomas, E. ,  TREVINO, Leo, A. ,  RANNY, Helen, M.

Inventor： ALLIANCE PHARMACEUTICAL CORP.

IPC: A61K09/00

CPC classification number: A61K9/0026

Abstract: A thermodynamically stable molecular solution providing enhanced bioavailability for pharmaceutical agents is disclosed. The solutions preferably comprise a liquid carrier comprising one or more physiologically acceptable lipophilic fluorochemicals and a pharmaceutically effective amount of at least one pharmaceutical agent solubilized in said liquid carrier to form a thermodynamically stable molecular solution. Optionally the thermodynamically stable solution comprises a co-solvent for facilitating solubilization of the pharmaceutical agent. Preferably the pharmaceutical agent is a lipophilic compound.

Abstract translation: 公开了提供药剂的增强的生物利用度的热力学稳定的分子溶液。 溶液优选包含液体载体，其包含一种或多种生理上可接受的亲脂性含氟化合物和药学有效量的至少一种溶解在所述液体载体中的药剂，以形成热力学稳定的分子溶液。 任选地，热力学稳定的溶液包括用于促进药剂溶解的共溶剂。 优选地，药剂是亲脂性化合物。

公开(公告)号：WO1998025514A1

公开(公告)日：1998-06-18

申请号：PCT/US1997022808

申请日：1997-12-10

Applicant: ALLIANCE PHARMACEUTICAL CORP.

Inventor： ALLIANCE PHARMACEUTICAL CORP. ,  FAITHFULL, Nicholas, Simon ,  RHOADES, Glenn

IPC: A61B05/00

CPC classification number: A61B5/412 ,  A61B5/0215 ,  A61B5/029 ,  A61B5/145 ,  A61B5/14539 ,  A61B5/1455 ,  A61B5/14551 ,  A61B5/742

Abstract: Systems and methods are described for calculating, in real-time, various oxygenation parameters including total oxygen transport (DO 2), mixed venous blood oxygen tension (RO 2) and mixed venous blood oxyhemoglobin saturation (SvO 2) in a patient. The system preferably uses a computer (140), an arterial pressure line (160) and a blood chemistry monitor (150) to assist a physician in accurately determining when to give a patient a blood transfusion or otherwise alter the clinical management of the patient.

Abstract translation: 描述了用于实时计算患者中各种氧合参数的系统和方法，包括总氧气输送（DO 2），混合静脉血氧压力（RO 2）和混合静脉血氧血红蛋白饱和度（SvO 2）。 系统优选地使用计算机（140），动脉压力管线（160）和血液化学监测器（150）来帮助医生准确地确定何时给予患者输血或以其他方式改变患者的临床管理。

公开(公告)号：WO1998005301A1

公开(公告)日：1998-02-12

申请号：PCT/US1997013054

申请日：1997-08-06

Applicant: ALLIANCE PHARMACEUTICAL CORP.

Inventor： ALLIANCE PHARMACEUTICAL CORP. ,  KRAFFT, Marie-Pierre ,  RIESS, Jean, G. ,  ZARIF, Leila

IPC: A61K09/113

CPC classification number: A61K9/0026 ,  A61K9/113

Abstract: Multiple emulsions comprising a discontinuous emulsified phase incorporating a highly polar liquid, a second component selected from the group consisting of fluorocarbons and hydrocarbons and a continuous hydrophobic phase are disclosed. In preferred embodiments, the hydrophobic phase may comprise a fluorocarbon or hydrocarbon. Additionally, the stable multiple emulsions of the present invention may further incorporate a bioactive agent and are particularly suitable for drug delivery including pulmonary drug delivery.

Abstract translation: 公开了包含包含高极性液体的不连续乳化相，选自碳氟化合物和烃的第二组分和连续疏水相的多重乳液。 在优选的实施方案中，疏水相可以包含碳氟化合物或烃。 此外，本发明的稳定的多重乳液可以进一步掺入生物活性剂，并且特别适用于药物递送，包括肺部药物递送。

公开(公告)号：WO1996040281A2

公开(公告)日：1996-12-19

申请号：PCT/US1996009068

申请日：1996-06-05

Applicant: ALLIANCE PHARMACEUTICAL CORP. ,  KABALNOV, Alexey ,  SCHUTT, Ernest, George ,  WEERS, Jeffry, Greg

Inventor： ALLIANCE PHARMACEUTICAL CORP.

IPC: A61K49/00

CPC classification number: A61K49/223 ,  A61K49/1806 ,  A61K49/226 ,  Y10S514/937

Abstract: Long lasting gas emulsions for ultrasound and magnetic resonance imaging contrast enhancement utilize low Ostwald coefficient fluoromono- and fluoropolyether compounds. Gas emulsions comprising microbubble preparations are disclosed wherein the microbubbles comprise fluoroethers such as perfluorodiglyme (CF3(OCF2CF2)2OCF3), perfluoromonoglyme (CF3OCF2CF2OCF3), perfluorodiethylether C2F5OC2F5, perfluoroethylmethylether CF3OC2F5, perfluorodimethylether CF3OCF3, as well as CF3OCF2OCF3 and fluoropolyethers CF3(OCF2)2OCF3, CF3(OCF2)3OCF3, and CF3(OCF2)4OCF3.

Abstract translation: 用于超声和磁共振成像对比度增强的持久性气体乳液利用低奥斯特瓦尔德系氟和氟聚醚化合物。 公开了包含微泡制剂的气体乳液，其中微泡包括氟代醚，例如全氟二甘醇二甲醚（CF 3（OCF 2 CF 2）2 OCF 3），全氟甘油（CF 3 OCF 2 CF 2 OCF 3），全氟二乙醚C 2 F 5 OC 2 F 5，全氟乙基甲基醚CF 3 OC 2 F 5，全氟二甲基醚CF 3 OCF 3，以及CF 3 OCF 2 OCF 3和氟聚醚CF 3（OCF 2）2 OCF 3，CF 3 （OCF 2）3 OCF 3和CF 3（OCF 2）4 OCF 3。

公开(公告)号：WO1996009793A1

公开(公告)日：1996-04-04

申请号：PCT/US1995012245

申请日：1995-09-26

Applicant: ALLIANCE PHARMACEUTICAL CORP.

Inventor： ALLIANCE PHARMACEUTICAL CORP. ,  SCHUTT, Ernest, G.

IPC: A61B08/00

CPC classification number: A61B8/481 ,  A61K49/223

Abstract: A method for ultrasonic harmonic imaging is disclosed, which uses microbubbles particularly selected for their properties of reradiating ultrasound energy at frequencies other than the exciting frequency. A contrast agent for ultrasonic harmonic imaging having the property of reradiating ultrasound energy at frequencies other than the exciting frequency is also disclosed.

Abstract translation: 公开了一种用于超声波谐波成像的方法，其使用特别选择用于在除了激励频率之外的频率再次辐射超声能量的性质的微泡。 还公开了一种用于超声波谐波成像的造影剂，其具有在除了激励频率之外的频率上重新辐射超声能量的性质。

公开(公告)号：WO1994009625A2

公开(公告)日：1994-05-11

申请号：PCT/US1993010286

申请日：1993-10-27

Applicant: ALLIANCE PHARMACEUTICAL CORP.

Inventor： ALLIANCE PHARMACEUTICAL CORP. ,  WEERS, Jeffry, Greg ,  KLEIN, David, Henry ,  JOHNSON, Cindy, Shizuko

IPC: A01N0

CPC classification number: A61K9/0026 ,  Y10S514/832 ,  Y10S514/937

Abstract: Storage stable fluorocarbon emulsions having a continuous aqueous phase and a discontinuous fluorocarbon phase, in which the fluorocarbon phase comprises a major amount of a first fluorocarbon or fluorocarbon mixture, and a minor amount of a second fluorocarbon or fluorocarbon mixture, in which the second fluorocarbon has a molecular weight greater than that of the first fluorocarbon and the second fluorocarbon includes a lipophilic moiety in its structure, whereby the second fluorocarbon serves to promote particle size stability in the emulsion while simultaneously providing favorably short organ retention times when administered to animals in vivo.

Abstract translation: 具有连续水相和不连续碳氟化合物相的储存稳定的碳氟化合物乳液，其中碳氟化合物相包含主要量的第一碳氟化合物或碳氟化合物混合物和少量第二碳氟化合物或碳氟化合物混合物，其中第二碳氟化合物具有 大于第一碳氟化合物和第二氟碳化合物的分子量包括其结构中的亲脂性部分，由此第二种氟碳化合物用于促进乳液中的粒度稳定性，同时在体内施用于动物时同时提供有利的短的器官保留时间。

公开(公告)号：WO1990001901A1

公开(公告)日：1990-03-08

申请号：PCT/US1989003556

申请日：1989-08-18

Applicant: ALLIANCE PHARMACEUTICAL CORP.

Inventor： ALLIANCE PHARMACEUTICAL CORP. ,  LONG, David, M.

IPC: A61B06/00

CPC classification number: A61B5/055 ,  A61K49/0471 ,  A61K49/1806 ,  Y10T436/24

Abstract: Perfluorocarbon hydrides, either alone or in combination with other perfluorocarbon compounds, may be introduced into a non-vascular animal space as a contrast agent in magnetic resonance imaging (MRI), computed tomography (CT) or conventional x-ray procedures. In the image generated by these systems, the fluorocarbon introduced into the space is contrasted with the remaining body tissues or spaces to distinguish the fluorocarbon-occupied space from other tissues and spaces. Perfluoroctyl hydride vaporizes at body temperature, and its gas phase, which also provides an effective contrast to tissues, is disclosed in imaging areas of comparatively large void volume while using a lower fluorocarbon dose then than required for fluid fluorocarbon. Perfluorocarbon hydrides offer less radiodensity to x-ray imaging and less hydrogen density to MRI imaging, and are disclosed as diluents for perfluorocarbon bromides in applications where concentrated brominated compounds are found to cause imaging artifacts. Perfluorocarbon emulsions comprising a mixture of perfluorocarbon bromide and at least 0.1% perfluorocarbon hydride are disclosed for intravascular use as a contrast agent or for oxygen transport.

公开(公告)号：WO1996040222A1

公开(公告)日：1996-12-19

申请号：PCT/US1996009990

申请日：1996-06-07

Applicant: ALLIANCE PHARMACEUTICAL CORP.

Inventor： ALLIANCE PHARMACEUTICAL CORP. ,  FAITHFULL, Nicholas, Simon ,  KEIPERT, Peter, E. ,  ROTH, Duane, J. ,  HOPKINS, Ronald, M.

IPC: A61K38/42

CPC classification number: A61K31/025 ,  A61K31/02 ,  A61K33/00 ,  A61K2300/00

Abstract: A method for hemodiluting a patient is disclosed which includes the steps of administering a biocompatible oxygen carrier in conjunction with surgery or organ ischemia or infarct while assessing the patient's PvO2 or other oxygenation indices, and administering to the patient additional oxygen carrier or autologous blood in response to the PvO2 value if necessary to maintain the PvO2 at or above the desired level.

Abstract translation: 公开了一种用于对患者进行血液稀释的方法，其包括以下步骤：在评估患者的PvO 2或其它氧合指数的同时给予生物相容性氧载体以结合手术或器官缺血或梗塞，并且向患者施用额外的氧载体或自体血液作为应答 如果需要，将PVO2保持在所需水平以上或更高。